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Introduction: Trastuzumab is generally considered a highly safe drug, but there have been cases of infusion
reaction and cardiotoxicity. This report will present a rare case of hepatotoxicity induced by trastuzumab used for
adjuvant therapy of human epidermal growth factor receptor type 2-positive breast cancer.
Case presentation: The patient was a 60-year-old Japanese postmenopausal woman with a non-contributory past
medical history. She presented for detailed examination of an abnormality in her left breast. She had left breast cancer
(T2N1M0, stage IIB) that was positive for estrogen receptor and progesterone receptor and was human epidermal
growth factor receptor type 2 3+. She began receiving epirubicin and cyclophosphamide therapy but developed
hepatotoxicity (aspartate aminotransferase 43U/L, alanine aminotransferase 104U/L, alkaline phosphatase 634U/L,
and γ-glutamyl transpeptidase 383U/L). Thus, the therapy was discontinued after two cycles, and a weekly paclitaxel
therapy was begun. After the absence of an adverse event was confirmed, she also began receiving trastuzumab
(4mg/kg) at the second cycle. However, hepatotoxicity (aspartate aminotransferase 267U/L, alanine aminotransferase
246U/L, alkaline phosphatase 553U/L, and γ-glutamyl transpeptidase 240U/L) developed again, and trastuzumab was
discontinued. She received paclitaxel monotherapy for a total of four cycles and subsequently underwent partial
mastectomy and axillary dissection. After completing adjuvant radiation therapy (breast, 50Gy), she received trastuzumab
administration (4mg/kg) but hepatotoxicity (aspartate aminotransferase 47U/L, alanine aminotransferase 102U/L, alkaline
phosphatase 377U/L, and γ-glutamyl transpeptidase 91U/L) recurred. Thus, it was discontinued again. There was
no hepatitis B or C virus infection, and a drug-induced lymphocyte stimulation test revealed a positive reaction to
trastuzumab (stimulation index: 227%). Thereafter she has used only oral letrozole (2.5mg/day) and no recurrent
cancer has been observed.
Conclusions: Although trastuzumab is a highly safe drug, one must be mindful of its risk for hepatotoxicity.
Periodic monitoring of liver functions is necessary during trastuzumab therapy.
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Trastuzumab is generally considered a highly safe drug,
but there have been cases of infusion reaction and cardio-
toxicity [1-4]. We report here a rare case of hepatotoxicity
induced by trastuzumab used for adjuvant therapy of
human epidermal growth factor receptor type 2 (HER2)-
positive breast cancer and we also include a brief literature
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The patient was a 60-year-old postmenopausal Japanese
woman with non-contributory past medical history, alco-
hol use at a social drinking level, and no history of
cigarette smoking. An abnormality was found in her left
breast during a physical examination at another hospital,
and she was referred and presented to our hospital for a
detailed examination in October 2011. The results of the
examination revealed left breast cancer (T2N1M0, stage
IIB) that was positive for estrogen receptor and progester-
one receptor and was HER2 3+. The treatment plan was
neoadjuvant chemotherapy. In November, she began re-
ceiving epirubicin and cyclophosphamide therapy (epiru-
bicin 75mg/m2, cyclophosphamide 600mg/m2, day 1 everyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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transferase (AST) 43U/L (Grade 1), alanine aminotrans-
ferase (ALT) 104U/L (Grade 1), alkaline phosphatase
(ALP) 634U/L (Grade 1), and glutamyl transpeptidase
(γ-GTP) 383U/L (Grade 3). Thus, the therapy was discon-
tinued after two cycles, and a weekly paclitaxel (PTX)
therapy (80mg/m2 on days 1, 8, and 15; every 4 weeks)
was begun. After the absence of adverse events was con-
firmed, she also began receiving trastuzumab at a loading
dose (4mg/kg) beginning with the second cycle. However,
hepatotoxicity (AST 267U/L, Grade 3; ALT 246U/L,
Grade 3; ALP 553U/L, Grade 1; and γ-GTP 240U/L,
Grade 3) developed again, and trastuzumab was discontin-
ued. There was no elevated bilirubin or abnormality in co-
agulation tests. After liver functions improved, she received
PTX monotherapy for a total of four cycles. In August
2012, she underwent partial mastectomy and axillary dis-
section, and the pathological diagnosis was papillotubular
carcinoma with a depth of invasion of 1.2cm, n-, ly0, v0,
negative margin, and histological response to chemother-
apy of grade 1b. After completing adjuvant radiation ther-
apy (breast, 50Gy), she was readministered trastuzumab
(4mg/kg) beginning in May 2013, but hepatotoxicity (AST
47U/L, Grade 1; ALT 102U/L, Grade 1; ALP 377U/L,
Grade 1; and γ-GTP 91U/L, Grade 2) recurred. Thus, it
was discontinued again (Figure 1). She was negative for
hepatitis C virus antibody and hepatitis B virus DNA,Figure 1 Treatment course and changes in hepatotoxicity. The patient
was based on the finding that hepatotoxicity developed not only for a co
monotherapy. Abbreviations: ALP, alkaline phosphatase (IU/L); ALT, alanine
epirubicin + cyclophosphamide; γ-GTP, γ glutamyl transpeptidase (IU/L); Pand there was no hepatitis B or C virus infection. A drug-
induced lymphocyte stimulation test (DLST) revealed a
positive reaction to trastuzumab (stimulation index: 227%).
Thereafter she has used only oral letrozole (2.5mg/day) and
no recurrent cancer has been observed as of May 2014.
Discussion
Overexpression of HER2 protein occurs in 20 to 30% of
breast cancers and is considered a predictor of poor prog-
nosis [5,6]. The prognosis of patients with such cancer has
improved greatly with the emergence of the molecularly
targeted drug trastuzumab [7,8]. Therefore, it is presently
used for advanced and metastatic breast cancer and is also
used frequently for adjuvant therapy. It is a major drug for
treatment of HER2-positive breast cancer.
The most significant adverse events of trastuzumab are
serious infusion reactions and cardiotoxicity [1-4]. Other
serious adverse events are rare in general clinical practice.
In particular, trastuzumab-induced hepatotoxicity is rare
and there are only three past reports in the English litera-
ture. These reports are described below.
In one report, Muñoz et al. presented a case of HER2-
positive breast cancer that underwent surgery and adjuvant
trastuzumab therapy (8mg/kg). The patient developed hep-
atotoxicity (AST, Grade 3; ALT, Grade 4), but liver function
tests showed normal values 1 month after trastuzumab was
discontinued. Therefore, trastuzumab was reintroduced atwas diagnosed with trastuzumab-induced hepatotoxicity. This diagnosis
mbination of trastuzumab and PTX therapy but also for trastuzumab
aminotransferase (IU/L); AST, aspartate aminotransferase (IU/L); EC,
TX, paclitaxel.
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without recurrence of hepatotoxicity. This patient had re-
ceived fluorouracil, doxorubicin, and cyclophosphamide
therapy up to 1 month before trastuzumab was begun and
had hepatotoxicity (AST, Grade 3; ALT, Grade 4). These
authors discussed that trastuzumab probably caused hepato-
toxicity in a dose-dependent manner, but chemotherapy-
induced hepatotoxicity also probably played a role in
trastuzumab-induced hepatotoxicity [9].
In another report, Srinivasan et al. presented a case of
HER2-positive breast cancer that underwent neoadju-
vant therapy (weekly PTX and trastuzumab). Conse-
quently, the patient developed hepatotoxicity (AST and
ALT, Grade 3; ALP, Grade 2). When trastuzumab was
reintroduced as monotherapy after surgery, she once
again developed hepatotoxicity (AST and ALT, Grade 3;
ALP, Grade 2) [10].
In still another report, Vucicevic et al. reported on a
case of HER2-positive breast cancer in which adjuvant
trastuzumab monotherapy was used. The patient devel-
oped hepatotoxicity 6 months after the first administra-
tion. In this patient, the transaminase level continued
to elevate for 2 months after trastuzumab was discon-
tinued (AST and ALT, Grade 3; ALP, Grade 2), but the
results of her liver function tests were normal on the
fourth month. These authors thought that the long
half-life of trastuzumab was a cause of prolonged hep-
atotoxicity [11].
Our patient did not have a family history of liver dis-
ease, was not taking any drug regularly, and had no
hepatitis B or C virus infection. She was diagnosed with
trastuzumab-induced hepatotoxicity. This diagnosis was
based on the finding that hepatotoxicity developed not
only for a combination of trastuzumab and PTX therapy
but also for trastuzumab monotherapy and that the DLST
revealed a positive reaction to trastuzumab.
Our patient is the fourth reported case of trastuzumab-
induced hepatotoxicity based on our literature search and
the first case in which trastuzumab was identified as the
causative drug using DLST. Two of the previous reported
cases had developed hepatotoxicity after the first adminis-
tration of trastuzumab. However, one case had developed
hepatotoxicity a while after beginning trastuzumab therapy
and, therefore, caution is required. When trastuzumab-
induced hepatotoxicity is detected early, liver dysfunction
can be reversed and more serious complications can be
prevented. Thus, periodic liver function tests are thought
to be necessary during trastuzumab therapy.Conclusions
Although trastuzumab is highly safe, one must be mindful
of its risk for hepatotoxicity and periodically perform liver
function tests during trastuzumab therapy.Consent
Written informed consent was obtained from the patient
for publication of this manuscript and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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